

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)	Atty Docket No. P1752R1	Serial No. 09/613,038
	Applicant Grillo-Lopez et al.	
	Filing Date 10 Jul 2000	Group 1636

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
QW	1	4,975,278	04.12.90	Senter, P. et al.			
	2	5,417,972	23.05.95	Bhat, N. M. et al.			
	3	5,540,926	30.07.96	Aruffo, A. et al.			
	4	5,587,459	24.12.96	Uckun			
	5	5,593,676	14.01.97	Bhat, N. M. et al.			
	6	5,595,721	21.01.97	Kaminski et al.			
	7	5,677,180	14.10.97	Robinson et al.			
	8	5,686,072	11.11.97	Uhr et al.			
	9	5,693,780	02.12.97	Newman, R. A. et al.			
	10	5,721,108	24.02.98	Robinson et al.			
	11	5,736,137	07.04.98	Anderson et al.			
	12	5,786,456	28.07.98	Ledbetter, J. A. et al.			
	13	5,795,569	18.08.98	Bartley et al.			
	14	5,872,223	16.02.99	Uckun			
QW	15	5,877,299	02.03.99	Thomas et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	16	405,972 A1	02.01.91	EPO				
	17	540,859 B1	14.01.98	EPO				
	18	585,943 B1	11.02.98	EPO				
	19	701,130 A2	13.03.96	EPO				
	20	WO 00/06694	10.02.00	PCT				
	21	WO 00/09160	24.02.00	PCT				
	22	WO 00/27428	18.05.00	PCT				
	23	WO 00/27433	18.05.00	PCT				
	24	WO 91/13974	19.09.91	PCT				
	25	WO 93/25673	23.12.93	PCT				
	26	WO 95/03770	09.02.95	PCT				
	27	WO 95/14230	26.05.95	PCT				
	28	WO 97/13529	17.04.97	PCT				
	29	WO 97/31025	28.08.97	PCT				
	30	WO 97/34633	25.09.97	PCT				
	31	WO 98/04281	05.02.98	PCT				
	32	WO 98/16254	23.04.98	PCT				
	33	WO 99/30738	24.06.99	PCT				

Examiner

Date Considered

Quay Nguyen

12/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1752R1

Serial No.

09/613,038

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | | |
|--------------|----|--|
| | 34 | "Amgen Discontinues Development of MGDF" (press release) (September 11, 1998) |
| | 35 | Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation" <u>Blood</u> 63(6):1424-1433 (1984) |
| Duplicate QW | 36 | Ballester et al., "Rituximab can be safely included as part of high-dose therapy/autologous stem cell transplantation for patients with Non-Hodgkin's lymphoma" <u>Blood</u> (Abstract #4552) 92(10 Suppl. 1 part 1-2):360b-361b (Nov 15, 1998) |
| | 37 | Bellon et al., "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" <u>Human Gene Therapy</u> 8:15-25 (1997) |
| Duplicate QW | 38 | Buckstein et al., "The effects of in vivo purging with Rituxan on stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patients with relapsed follicular lymphoma undergoing autologous stem cell transplant" <u>Blood</u> (Abstract #2672) 92(10 Suppl. 1 Part 1-2):647a (1998) |
| | 39 | Bussel, J.B., "Autoimmune Thrombocytopenic Purpura" <u>Hematology - Oncology Clinics of North America</u> 4(1):179-191 (Feb 1990) |
| | 40 | Christ et al., "Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response" <u>Immunology Letters</u> 57:19-25 (1997) |
| Duplicate QW | 41 | Cook et al., "Effective Treatment of Lymphoproliferative Disease following Lung Transplantation using Monoclonal Anti-CD20 B-Cell Antibody" <u>The Journal of Heart and Lung Transplantation</u> (abstract only) 18:84-85 (January 1999) |
| | 42 | Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs" <u>Cancer Biotherapy & Radiopharmaceuticals</u> 12(3):177-186 (1997) |
| | 43 | Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" <u>EMBO Journal</u> 7(3):711-717 (1988) |
| Duplicate QW | 44 | Faye et al., "Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders" <u>Lancet</u> 352:1285 (Oct 17, 1998) |
| Duplicate QW | 45 | Flinn et al., "In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL" <u>Blood</u> (Abstract #2673) 92(10 Suppl 2 part 1-2):648a (Nov 15, 1998) |
| | 46 | George et al., "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology" <u>Blood</u> 88(1):3-40 (Jul 1, 1996) |
| Duplicate QW | 47 | John et al., "Anti-CD20 monoclonal antibody for the treatment of post-transplant lymphoproliferative disease in a pediatric heart transplant recipient." <u>Journal of Investigative Medicine</u> 4(2):125A (Feb 1999) |
| | 48 | Johnston, "Rituximab-Associated Immune Thrombocytopenic Purpura" <u>Blood</u> 94(10):4386 (1999) |
| | 49 | Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity" <u>Leukemia Research</u> 11(12):1119-1125 (1987) |
| | 50 | Knoell, "Clinical Aspects of Gene Therapy" <u>The Annals of Pharmacotherapy</u> 32:977-979 (September 1998) |
| | 51 | Korholz et al., "Humoral immunodeficiency in patients after bone marrow transplantation" <u>Bone Marrow Transplantation</u> 18:1123-1130 (1996) |
| Duplicate QW | 52 | Lee et al., "Rituxan in the treatment of cold agglutinin disease" <u>Blood</u> 92(9):3490-3491 (Nov 1, 1998) |

Examiner

Quang Nguyen

Date Considered

12/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1752R1

Serial No.

09/613,038

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- 53 Levine et al., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab" Neurology 52:1701-1704 (May 12, 1999)
- 54 Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (nhl) cell lines" Blood (Abstract #2535) 88(10):637a (1996)
- 55 Mow et al., "Rituximab for the Treatment of Refractory Immune Thrombocytopenic Purpura - Case Report" Blood 94:3526 (1999)
- 56 Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes" J. Immunol. 131(1):244-250 (Jul 1983)
- 57 Nadler et al., "Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies" Progress in Hematology, Brown, E., Grune & Stratton, Inc. Vol. XII:187-225 (1981)
- 58 Nadler, L. Lymphocyte Typing II, Renling et al., Springer Verlag Vol. 2:3-37 and Appendix (1986)
- 59 Notoya et al., "Chronic cold agglutinin disease accompanied with an increase of CD20⁺/CD5⁺ cells; a case report" The Japanese Journal of Clinical Hematology (English language abstract of attached Japanese article) 35(9):881-885 (Sep 1994)
- 60 Ooto et al., "Quantitative Flowcytometric Analysis of B Cell Surface Antigens in Patients with Autoimmune Diseases" The Japanese Journal of Clinical Pathology (English language abstract of attached Japanese article) 43(4):381-384 (Apr 1995)
- 61 Pai-Scherf et al., "A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab" (Clinical Research Proposal)
- 62 Paulus et al., "Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo" Athritis Rheum. 33(4):477-484 (Apr 1990)
- 63 Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to Rituximab" Blood (Abstract #3360) 92 (Nov 1998)
- 64 Pescovitz, "Pilot Study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Clinical Trial Proposal)
- 65 Pescovitz, "Pilot study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Letter to Dr. Grillo-Lopez and Protocol Concept Sheet)
- 66 Plascik, P., "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer" Journal of the American Pharmaceutical Association 38(3):379-380 (May/Jun 1998)
- 67 Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" Blood 83(2):435-445 (Jan 15, 1994)
- 68 Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies" Blood 91(5):1644-1652 (Mar 1, 1998)
- 69 Sollinger (Letter to Dr. Bonni S. Dutcher) (December 23, 1998)
- 70 Sollinger, "Phase 2 trial using Rituxin to desensitize patients awaiting renal transplant" (Investigator Initiated Protocol Concept Worksheet)
- 71 Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation" The Journal of Immunology 135(2):973-979 (1985)
- 72 Tedder et al., "The CD20 surface molecule of B lymphocytes functions as a calcium channel" J. Cell. Biochem. (Abstract # M 023) 14D:195 (1990)

Examiner

Quay Nguyen

Date Considered

12/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1752R1

Serial No.

09/613,038

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 73 | Vaile et al., "Bowel Permeability and CD45RO Expression on Circulating CD20+ B Cells in Patients with Ankylosing Spondylitis and Their Relatives" <u>The Journal of Rheumatology</u> 26(1):128-135 (1999) |
| 74 | Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes" <u>Journal of Biological Chemistry</u> 264(19):11282-11287 (Jul 5, 1989) |
| 75 | Vassilev et al., "Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)" <u>Clin. Exp. Immunol.</u> 92:369-372 (Feb 25, 1993) |
| 76 | Watson et al., "A case of germinal center formation by CD45RO T and CD20 B lymphocytes in rheumatoid arthritic subchondral bone: proposal for a two-compartment model of immune-mediated disease with implications for immunotherapeutic strategies" <u>Clinical Immunology and Immunopathology</u> 73(1):27-37 (1994) |
| 77 | Wilkes et al., "Preferential production of IgG2 antibodies by parenchymal lung B-lymphocytes during lung allograft rejection" <u>Transplantation Proceedings</u> 29:1891-1895 (1997) |
| 78 | Yokose et al., "Low-grade B cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with rheumatoid arthritis" <u>Pathology International</u> 48:74-81 (1998) |
| 79 | Yu and Lennon, "Mechanism of Intravenous immune globulin therapy in antibody-mediated autoimmune diseases" <u>New England J. of Medicine</u> 340(3):227-228 (Jan 21, 1999) |


RECEIVED
JUN 14 2002
TECH CENTER 1600/2900

Examiner

Date Considered

12/23/02

*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Serial No.
09/613,038

Group
~~1632~~

U.S. PATENT DOCUMENTS

RECEIVED
FEB 07 2002
MAILING DATE
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and (not considered. Include copy of this form with next communication to applicant.